FINOSE / Joint Nordic HTA-Bodies (JNHB) joint assessment framework
A collaborative framework among Nordic health technology assessment agencies that produces a single joint assessment of a health technology's effectiveness and cost-effectiveness, used to inform national reimbursement and procurement decisions in Nordic countries.
At a glance
Use when
When conducting HTA for pharmaceuticals or health technologies intended for multiple Nordic countries; when seeking to streamline assessment processes across Nordic jurisdictions
Avoid when
When country-specific contextual factors significantly differ and require separate evaluation; when national HTA agencies do not participate in the collaboration; for non-Nordic market assessments
Inputs
Clinical trial data, health economic models, real-world evidence, and contextual data relevant to Nordic healthcare systems
Outputs
Joint English assessment report on relative effectiveness and health economics used for national reimbursement and procurement decisions
How it works
The FINOSE framework enables coordinated assessment processes across Fimea (Finland), NoMA/DMP (Norway), TLV (Sweden), and Medicinrådet (Denmark), generating a unified English-language report on relative effectiveness and health economics. This joint assessment supports national decision-making while reducing duplication of efforts and accelerating time to market for pharmaceuticals in the Nordic region.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Organisational aspects
- Assumptions
- Assumes alignment in methodological standards across participating agencies; assumes that joint assessments can be efficiently integrated into national decision-making processes; assumes sufficient data availability in English for cross-country evaluation
- Strengths
- Reduces duplication of assessment work; accelerates time to market; enhances consistency and transparency across Nordic HTA processes; leverages shared expertise and resources
- Limitations
- May not fully capture country-specific clinical or organizational contexts; national decisions may still diverge despite joint assessment; limited applicability outside the Nordic region
- Also known as
- FINOSE, Joint Nordic HTA-Bodies framework, JNHB framework
Questions this answers
- › How effective is a health technology compared to existing alternatives?
- › What is the cost-effectiveness of the technology in the Nordic context?
- › How do organisational aspects affect the implementation of the technology in Nordic healthcare systems?
- › How can joint HTA processes reduce duplication and accelerate market access?
- › What are the agreed-upon methodological standards across Nordic HTA bodies?
- › How can cross-country collaboration improve the robustness of HTA assessments?
References & sources
Similar by meaning
Beta record. Based on the original catalogue summary; primary-source enrichment pending.